Barely Significant
← all excerpts

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.

Lancet · 2020 · PMC6961114 · PMID 31839281

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp<0·0001actually significant
250 breast cancers have been reported (85 anastrozole [4·4%] vs 165 placebo [8·5%]; table 1 ), with a highly significant 49% reduction for all breast cancer with anastrozole (HR 0·51, 95% CI 0·39–0·66, p<0·0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.